ATLANTA, Feb. 4 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), an Atlanta-based, publicly traded biopharmaceutical company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, today announced that its Corporate Presentation at the BIO CEO & Investor Conference 2009 will be webcast live by Thomson Reuters. The Conference will be held at the Waldorf-Astoria Hotel in New York City on February 9 and 10, 2009.
Dr. McNally, CEO and President of GeoVax Labs, Inc., will present an overview of GeoVax's vaccine technology and will report the latest progress on the Company's Phase 2a preventative human vaccine trial and plans for upcoming therapeutic human vaccine trials.
GeoVax's live webcast coverage is scheduled to commence at 11:00 AM Eastern, on February 10, 2009. The presentation may be accessed by visiting the Company's website at:
http://www.geovax.com or http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=GOVX&item_id=2086228
Participants can log-in approximately 15 minutes prior to the scheduled presentation in order to register and download any necessary software. A replay of the webcast will also be available on the Company's website following the event for a period of 90 days.
The BIO CEO & Investor Conference is the preeminent gathering of cutting
edge biotechnology companies, represented by senior executives, presenting
their achievements to institutional investors, industry analysts and portfolio
senior executives. Presenting companies were selected through a competitive
screening process with a focus on their potential to deliver near-term
clinical accomplishments in areas of unmet medical need. The
|SOURCE GeoVax Labs, Inc.|
Copyright©2009 PR Newswire.
All rights reserved